Ataxin-3 (ATXN3) is a deubiquitinase enzyme encoded by the ATXN3 gene that plays critical roles in protein quality control, transcriptional regulation, and DNA repair. The protein is best known for its involvement in Spinocerebellar Ataxia Type 3 (SCA3/MJD), but also participates in pathways relevant to Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Ataxin-3 contains a unique Josephin domain with catalytic activity and a polyglutamine (polyQ) tract whose expansion causes disease.
Ataxin-3 represents a fascinating intersection between polyglutamine diseases and broader neurodegenerative mechanisms. Originally identified as the causative protein in Spinocerebellar Ataxia Type 3, the most common dominantly inherited ataxia worldwide, Ataxin-3 has emerged as an important regulator of cellular protein homeostasis. The protein's normal functions in the ubiquitin-proteasome system and transcriptional control have significant implications for understanding and treating various neurodegenerative diseases.
| Property |
Value |
| Protein Name |
Ataxin-3 |
| Gene Symbol |
ATXN3 |
| UniProt ID |
P54259 |
| Molecular Weight |
~42 kDa (variable due to polyQ length) |
| Subcellular Localization |
Nucleus, Cytoplasm |
| Protein Family |
Ataxin family, Josephin domain family |
| Aliases |
SCA3, MJD1, Josephin |
¶ Josephin Domain
The N-terminal Josephin domain (~180 amino acids) contains the catalytic machinery:
- Catalytic Cysteine: Cys178 forms the nucleophilic attack on ubiquitin
- Active Site Pocket: Binds ubiquitin for cleavage
- ZnF-UBP Domain: Zinc-finger ubiquitin-binding domain at the C-terminus
- Normal Range: 12-44 glutamine residues
- Disease Range: 52-86 glutamine residues (pathogenic expansion)
- Variable Length: Causes phenotypic variability in SCA3
¶ Additional Domains
- Multiple UIMs (Ubiquitin-Interacting Motifs): 3 UIMs for ubiquitin binding
- Nuclear Localization Signals: Support nuclear-cytoplasmic shuttling
- Phosphorylation Sites: Modulate protein function and aggregation
Ataxin-3 functions as a deubiquitinase (DUB):
- Chain Editing: Removes specific ubiquitin chains, regulating protein degradation
- Chain Trimming: Cleaves ubiquitin from substrates for recycling
- Quality Control: Prevents accumulation of misfolded ubiquitinated proteins
- Proteasome Regulation: Modulates proteasomal activity through deubiquitination
- Aggregate Clearance: Helps clear protein aggregates in cellular stress
- Chaperone Coordination: Works with molecular chaperones for protein folding
- Histone Modifications: Deubiquitinates histones H2A and H2B
- Transcription Factor Control: Regulates MAF1, other transcriptional regulators
- Chromatin Remodeling: Influences transcriptional programs
- Genome Stability: Participates in DNA damage response
- Transcription-Coupled Repair: Coordinates with NER pathways
- Checkpoint Regulation: Modulates cell cycle checkpoints
Also known as Machado-Joseph Disease (MJD)
SCA3 is caused by CAG trinucleotide repeat expansion in the ATXN3 gene:
- Pathogenesis: Expanded polyQ tract causes toxic gain-of-function
- Aggregation: Mutant Ataxin-3 forms insoluble aggregates in neurons
- Selective Vulnerability: Particularly affects cerebellar dentate nuclei, brainstem, spinal cord
- Clinical Features: Ataxia, dystonia, ophthalmoplegia, peripheral neuropathy
- APP Processing: Ataxin-3 interacts with APP and influences amyloid-beta production
- Tau Pathology: Modulates tau ubiquitination and aggregation
- Neuronal Survival: Loss of function may contribute to AD progression
- Alpha-Synuclein Clearance: Ataxin-3 participates in regulating alpha-synuclein degradation
- Mitochondrial Quality Control: Modulates mitophagy pathways
- Parkin Interactions: Cooperates with E3 ligase Parkin
- TDP-43 Regulation: Ataxin-3 can deubiquitinate TDP-43 aggregates
- Protein Homeostasis: Contributes to motor neuron protein quality control
- Stress Granule Dynamics: Modulates stress granule formation and clearance
- Huntington's Disease: Modulates mutant huntingtin aggregation
- Frontotemporal Dementia: Interacts with TDP-43 pathology
- Prion Diseases: May influence prion protein clearance
-
PolyQ Reduction
- ASO (antisense oligonucleotide) approaches to reduce mutant ATXN3
- CRISPR-based gene editing
-
Aggregation Modulation
- Compounds that prevent aggregate formation
- Enhanced clearance via autophagy induction
-
Deubiquitinase Modulation
- Enhancing normal Ataxin-3 function
- Inhibiting pathogenic interactions
-
Neuroprotective Strategies
- Mitochondrial protectants
- Antioxidant therapies
- Synaptic preservation
- ATXN3 Expression: Peripheral blood mononuclear cell levels
- Aggregate Markers: Detection of ATXN3 aggregates in CSF
- Genetic Testing: Predictive testing for at-risk individuals
| Protein |
Interaction Type |
Functional Consequence |
| VCP/p97 |
Co-factors |
Segregation of ubiquitinated substrates |
| Hsp70 |
Chaperone |
Protein folding and aggregate clearance |
| Parkin |
E3 ligase |
Mitophagy coordination |
| TDP-43 |
RNA binding |
Aggregate dynamics |
| p53 |
Transcription |
Cell death regulation |
Ataxin-3 shows preference for:
- K63-linked chains (polyubiquitin)
- K48-linked chains (proteasomal targeting)
- Mixed-linkage chains
- Pre-symptomatic testing: Available for at-risk individuals
- Prenatal diagnosis: For families with known mutations
- Carrier detection: Important for genetic counseling
- Symptomatic treatment: Physical therapy, assistive devices
- Pharmacological approaches: Targeting specific symptoms
- Experimental therapies: Clinical trials for disease-modifying treatments
- Mouse models: Transgenic and knock-in models
- iPSC-derived neurons: Patient-specific disease modeling
- In vitro systems: Purified protein aggregation assays
The study of Ataxin 3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Spinocerebellar ataxia type 3: pathogenesis and therapy
- Ataxin-3 deubiquitinase function and dysfunction
- Polyglutamine diseases: molecular mechanisms
- Ataxin-3 in Alzheimer's disease models
- Protein quality control in neurodegeneration
- Ataxin-3 and alpha-synuclein interactions
- Josephin domain structure and catalysis
- Therapeutic approaches to polyglutamine diseases